[Evaluation of the effect of nitazoxanide compared with placebo in patients with flatulence at the ambulatory consultation of the Central Clinic of Inppares-Lima].
Flatulence is a very common complaint related to functional gastrointestinal disorders. We know functional disorders is the main cause of consultation in gastroenterology offices. We don't know the exact reason of flatulence, but the intestinal fermentative microbiota could be an important etiologic factor. The objective of the study is to evaluate the effectiveness of the Nitazoxanida, on the clinical improvement of the flatulence in a group of patients of ambulatory consultation with respect to another group that receives placebo. The present article, is a controlled randomized clinical study designed to double blind, in whom 120 patients with flatulence criteria participate, of which 60 patients received Nitazoxanida 500mg, every 12 hours by 3 days, and the next 60 patients received placebo every 12 hours by 3 days, after one week were reevaluated, and they were put under a test of perception about clinical improvement (Jerome Frank). The Nitazoxanida group and the placebo group were very similar in age, sex, symptoms to the entrance, presence of anxiety, depression and upheavals of the dream. In the Nitazoxanida group was an average of improvement of 4.02 (75.31%) DS 0.94 and with placebo 2.35 (19.58%) D.S. 0.63. with percentage of 0.001 error. Being the perception of global improvement in the Nitazoxanida group 91.67% and in the placebo group 36.67%. Which is statistically significant. The study conclude that Nitozoxanide group produce a significative improvement in the perception of relief of flatulence in comparison to the placebo group. The study sets out a new therapeutic indication of the active principle Nitazoxanide, in flatulence. We found is a high prevalence of anxiety, depression and of upheavals of the dream in patients with flatulence.
Venero Nazario
Bremen
B
Médico gastrenterólogo Clínica Central INPPARES.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000554:Ambulatory Care Facilities; D004311:Double-Blind Method; D005260:Female; D005414:Flatulence / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009574:Nitro Compounds; D010568:Peru; D013844:Thiazoles / Q000627:therapeutic use*
D009574:Nitro Compounds; D013844:Thiazoles; C041747:nitazoxanide